The glycopeptide CSF114(Glc) detects serum antibodies in multiple sclerosis.
- Lolli F
- Mazzanti B
- Pazzagli M
- Peroni E
- Alcaro MC
- Sabatino G
- Lanzillo R
- Brescia Morra V
- Santoro L
- Gasperini C
- Galgani S
- D'Elios MM
- Zipoli V
- Sotgiu S
- Pugliatti M
- Rovero P
- Chelli M
- Papini AM
DOIAbstract
Synthetic glycopeptides have the potential to detect antibodies in multiple sclerosis (MS). In the present study, we analyzed the antibodies (IgM class, IgG class and IgG subclasses) to the synthetic glycopeptide CSF114(Glc) in the serum of 186 MS patients, 166 blood donors (BDs), 25 patients affected by meningitis/encephalitis, 41 affected by systemic lupus erythematosus (SLE) and 49 affected by rheumatoid arthritis (RA). The IgM antibody level to CSF114(Glc) was significantly increased in MS patients versus BDs (p<0.001) or versus other autoimmune diseases (SLE or RA, p<0.001). The IgG response was restricted to the subclass IgG2. IgM antibodies to CSF114(Glc) were found in 30% of relapsing/remitting MS patients and, at lower levels, ...
Add to ORKG